AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-8. (Cancelled).

9. (Original) A method of boosting a CD8+ T cell immune response to an antigen in an individual, the method including provision in the individual of a replication-deficient adenoviral vector including nucleic acid encoding the antigen or a CD8+ T cell epitope of said antigen operably linked to regulatory sequences for production of said antigen or epitope in the individual by expression from the nucleic acid, whereby a CD8+ T cell immune response to the antigen previously primed with a non-adenoviral vector in the individual is boosted.

10. (Currently Amended) A method of inducing a CD8+ T cell immune response to an antigen in an individual, the method comprising administering to the individual a priming composition comprising the antigen or a CD8+ T cell epitope of said antigen or nucleic acid encoding said antigen or epitope and then administering a heterologous boosting composition which comprises a replication-deficient adenoviral vector including nucleic acid encoding said antigen or epitope operably linked to regulatory sequences for production of said antigen or epitope in the individual by expression from the nucleic acid.

11. (Original) A method according to claim 10 wherein the priming composition comprises DNA encoding said antigen or epitope.

12. (Original) A method according to claim 10 wherein the priming composition comprises recombinant Ty-VLP

13. (Original) A method according to claim 10 wherein the priming composition comprises Modified Virus Ankara (MVA).

14. (Previously Presented) A method according to claim 9 further comprising administration of another, different boosting composition comprising said antigen or epitope.

15. (Previously Presented) A method according to claims 9 wherein the boosting composition is administered intradermally.

16. (Previously Presented) A method according to claim 9 wherein the boosting composition is administered intramuscularly.

17. (New) A method according to claim 10 wherein the priming composition is a non-adenoviral composition.

18. (New) A method according to claim 10 wherein the priming composition comprises a viral vector.

19. (New) A method according to claim 18 wherein the priming composition comprises a vaccinia virus vector.

20. (New) A method according to claim 18 wherein the priming composition comprises an avipox vector.

21. (New) A method according to claim 18 wherein the priming composition comprises a herpes virus vector.